Photodynamic therapy with 5-aminolevulinic acid and diamino acid derivatives of protoporphyrin IX reduces papillomas in mice without eliminating transformation into squamous cell carcinoma of the skin

International Journal of Cancer

Volumn 125, Issue 7, 2009, Pages 1721-1727

  Kwitniewski, Mateusz ^a,b   Jankowski, Dawid ^c   Jaskiewicz, Kazimierz ^a   Dziadziuszko, Halina ^a   Juzeniene, Asta ^b   Moan, Johan ^b,d   Ma, Li Wei ^b   Peksa, Rafal ^a   Kunikowska, Danuta ^a   Graczyk, Alfreda ^e   Kwasny, Miroslaw ^e   Kaliszewski, Miron ^e   Glosnicka, Renata ^f  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF GDA SK   (Poland)

^d UNIVERSITY OF OSLO   (Norway)

^e MILITARY UNIVERSITY OF TECHNOLOGY   (Poland)

^f R and D Immunolab Company Ltd   (Poland)

Author keywords

Papilloma; Photodynamic therapy; Photosensitizers; Porphyrins; Squamous cell carcinoma

Indexed keywords

AMINOLEVULINIC ACID; DIAMINO ACID; DIMETHYLBENZ[A]ANTHRACENE; PHORBOL 13 ACETATE 12 MYRISTATE; PHOTOSENSITIZING AGENT; PROTOPORPHYRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CONTROLLED STUDY; DRUG EFFICACY; MOUSE; NONHUMAN; PAPILLOMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY;

9,10-DIMETHYL-1,2-BENZANTHRACENE; AMINOLEVULINIC ACID; ANIMALS; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; KAPLAN-MEIERS ESTIMATE; MICE; MICE, INBRED STRAINS; PAPILLOMA; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE;

EID: 68549139982     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24488     Document Type: Article

References (54)

1. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004;5:497-508.
2. Ethirajan M, Saenz C, Gupta A, Dobhal MP, Pandey RK. Photosensitizers for photodynamic therapy and imaging. In: Hamblin MR, Mróz P, eds. Advances in photodynamic therapy: basic, translational, and clinical. Boston-London: Artech House, 2008, 13-39.
3. Berg K, Selbo PK, Weyergang A, Dietze A, Prasmickaite L, Bonsted A, Engesaeter BØ, Angell-Petersen E, Warloe T, Frandsen N, Høgset A. Porphyrin-related photosensitizers for cancer imaging and therapeutic applications. J Microsc 2005;218:133-47.
4. MacCormack MA. Photodynamic therapy in dermatology: an update on applications and outcomes. Semin Cutan Med Surg 2008;27:52-62.
5. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part two - cellular signaling, cell metabolism and modes of cell death. Photodiagn Photodyn Ther 2005;2:1-23.
6. Morton CA, Brown SB, Collins S, Ibbotson S, Jenkinson H, Kurwa H, Langmack K, McKenna K, Moseley H, Pearse AD, Stringer M, Taylor DK, et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 2002;146:552-67.
7. Fuchs J, Weber S, Kaufmann R. Genotoxic potential of porphyrin type photosensitizers with particular emphasis on 5-aminolevulinic acid: implications for clinical photodynamic therapy. Free Radic Biol Med 2000;28:537-48.
8. Wolf P, Fink-Puches R, Reimann-Weber A, Kerl H. Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site. Dermatology 1997;194:53-4.
9. Varma S, Holt PJ, Anstey AV. Erythroplasia of queyrat treated by topical aminolaevulinic acid photodynamic therapy: a cautionary tale. Br J Dermatol 2000;142:825-6.
10. Maydan E, Nootheti PK, Goldman MP. Development of a keratoacanthoma after topical photodynamic therapy with 5-aminolevulinic acid. J Drugs Dermatol 2006;5:804-6.
11. Stender IM, Bech-Thomsen N, Poulsen T, Wulf HC. Photodynamic therapy with topical delta-aminolevulinic acid delays UV photocarcinogenesis in hairless mice. Photochem Photobiol 1997;66:493-6.
12. Sharfaei S, Viau G, Lui H, Bouffard D, Bissonnette R. Systemic photodynamic therapy with aminolaevulinic acid delays the appearance of ultraviolet-induced skin tumours in mice. Br J Dermatol 2001;144:1207-14.
13. Sharfaei S, Juzenas P, Moan J, Bissonnette R. Weekly topical application of methyl aminolevulinate followed by light exposure delays the appearance of UV-induced skin tumours in mice. Arch Dermatol Res 2002;294:237-42.
14. Moan J, Bissonnette R. Skin preparation. Patent. 10/275,557 US 6,911,194 B2 2001.
15. Giri U, Iqbal M, Athar M. Porphyrin-mediated photosensitization has a weak tumor promoting activity in mouse skin: possible role of in situ-generated reactive oxygen species. Carcinogenesis 1996;17:2023-8.
16. Athar M, Lloyd JR, Bickers DR, Mukhtar H. Malignant conversion of UV radiation and chemically induced mouse skin benign tumors by free-radical-generating compounds. Carcinogenesis 1989;10:1841-5.
17. Bhasin G, Kauser H, Athar M. Free radical generating agents lead to the rapid progression of benign skin tumors to carcinoma in iron-overloaded mice. Arch Toxicol 2004;78:139-46.
18. Zoladek T, Nguyen BN, Jagiello I, Graczyk A, Rytka J. Diamino acid derivatives of porphyrins penetrate into yeast cells, induce photodamage, but have no mutagenic effect. Photochem Photobiol 1997;66: 253-9.
19. Kwitniewski M, Kunikowska D, Dera-Tomaszewska B, Tokarska-Pietrzak E, Dziadziuszko H, Graczyk A, Glosnicka R. Influence of diamino acid derivatives of protoporphyrin IX on mouse immunological system: preliminary results. J Photochem Photobiol B 2005;81: 129-35.
20. Graczyk A, Konarski J. Complex salts of hematoporphyrin and of its derivatives, their synthesis, and therapeutic agent. US patent no. 5451599, 1995.
21. Owens DM, Wei S, Smart RC. A multihit, multistage model of chemical carcinogenesis. Carcinogenesis 1999;20:1837-44.
22. Bugaj A, Kwitniewski M, Iani V, Juzeniene A, Juzenas P, Ma LW, Moan J. Photodynamic therapy with di-L-arginine protoporphyrinate on WiDr human colon adenocarcinoma xenografts in athymic nude mice. Photodiagn Photodyn Ther 2007;4:237-41.
23. Athar M, Agarwal R, Wang ZY, Lloyd JR, Bickers DR, Mukhtar H. All-trans retinoic acid protects against conversion of chemically induced and ultraviolet B radiation-induced skin papillomas to carcinomas. Carcinogenesis 1991;12:2325-9.
24. Hix LM, Lockwood SF, Bertram JS. Bioactive carotenoids: potent antioxidants and regulators of gene expression. Redox Rep 2004;9: 181-91.
25. Conte da Frota ML, Gomes da Silva E, Behr GA, Roberto de Oliveira M, Dal-Pizzol F, Klamt F, Moreira JC. All-trans retinoic acid induces free radical generation and modulate antioxidant enzyme activities in rat sertoli cells. Mol Cell Biochem 2006;285:173-9.
26. Pasquali MA, Gelain DP, Zanotto-Filho A, de Souza LF, de Oliveira RB, Klamt F, Moreira JC. Retinol and retinoic acid modulate catalase activity in Sertoli cells by distinct and gene expression-independent mechanisms. Toxicol In Vitro 2008;22:1177-83.
27. Gupta A, Butts B, Kwei KA, Dvorakova K, Stratton SP, Briehl MM, Bowden GT. Attenuation of catalase activity in the malignant pheno-type plays a functional role in an in vitro model for tumor progression. Cancer Lett 2001;173:115-25.
28. Kwei KA, Finch JS, Thompson EJ, Bowden GT. Transcriptional repression of catalase in mouse skin tumor progression. Neoplasia 2004;6:440-8.
29. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagn Photodyn Ther 2004;1:279-93.
30. Giri U, Iqbal M, Agarwal MK, Khan S, Athar M. Augmentation of 12-O-tetradecanoyl 13-phorbol acetate-mediated tumor promoting response by the porphyrin photosensitization of 7,12-dimethyl benz[a]anthracene-initiated murine skin: role of in situ generated reactive oxygen species. Cancer Lett 1999;135:53-60.
31. Giri U, Sharma SD, Abdulla M, Athar M. Evidence that in situ generated reactive oxygen species act as a potent stage I tumor promoter in mouse skin. Biochem Biophys Res Commun 1995;209: 698-705.
32. Nowis D, Stokłosa T, Legat M, Issat T, Jakobisiak M, Golab J. The influence of photodynamic therapy on the immune response. Photodiagn Photodyn Ther 2005;2:283-98.
33. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 2006;6:535-45.
34. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860-7.
35. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6: 24-37.
36. Darwiche N, Ryscavage A, Perez-Lorenzo R, Wright L, Bae DS, Hennings H, Yuspa SH, Glick AB. Expression profile of skin papillomas with high cancer risk displays a unique genetic signature that clusters with squamous cell carcinomas and predicts risk for malignant conversion. Oncogene 2007;26:6885-95.
37. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005;7:411-23.
38. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001;294:605-9.
39. Halliday G, MacCarrick G, Muller H. Tumour promoters but not initiators deplete Langerhans cells from murine epidermis. Br J Cancer 1987;56:328-30.
40. Muller H, Halliday G, Knight B. Carcinogen-induced depletion of cutaneous Langerhans cells. Br J Cancer 1985;52:81-5.
41. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 1982; 257:7847-51.
42. Nishihira J, O'Flaherty J. Phorbol myristate acetate receptors in human polymorphonuclear neutrophils. J Immunol 1985;135:3439-47.
43. McCord J. The evolution of free radicals and oxidative stress. Am J Med 2000;108:652-9.
44. Zhao Y, Xue Y, Oberley TD, Kiningham KK, Lin SM, Yen HC, Majima H, Hines J, St Clair D. Overexpression of manganese superoxide dismutase suppresses tumor formation by modulation of activator protein-1 signaling in a multistage skin carcinogenesis model. Cancer Res 2001;61:6082-8.
45. Brown K, Balmain A. Transgenic mice and squamous multistage skin carcinogenesis. Cancer Metastasis Rev 1995;14:113-24.
46. Slaga TJ. Multistage skin carcinogenesis: a useful model for the study of the chemoprevention of cancer. Acta Pharmacol Toxicol (Copenh) 1984;55 (Suppl 2):107-24.
47. de Visser KE. Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both? Cancer Immunol Immun-other 2008;57:1531-9.
48. Kwitniewski M, Juzeniene A, Ma LW, Glosnicka R, Graczyk A, Moan J. Diamino acid derivatives of PpIX as potential photosensitizers for photodynamic therapy of squamous cell carcinoma and prostate cancer: in vitro studies. J Photochem Photobiol B 2009;94: 214-22.
49. Grinholc M, Szramka B, Olender K, Graczyk A. Bactericidal effect of photodynamic therapy against methicillin-resistant Staphylococcus aureus strain with the use of various porphyrin photosensitizers. Acta Biochim Pol 2007;54:665-70.
50. Grinholc M, Kawiak A, Kurlenda J, Graczyk A, Bielawski KP. Photodynamic effect of protoporphyrin diarginate (PPArg2) on methicillin-resistant Staphylococcus aureus and human dermal fibroblasts. Acta Biochim Pol 2008;55:85-90.
51. Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008;159:1245-66.
52. Woodworth CD, Michael E, Smith L, Vijayachandra K, Glick A, Hennings H, Yuspa SH. Strain-dependent differences in malignant conversion of mouse skin tumors is an inherent property of the epidermal keratinocyte. Carcinogenesis 2004;25:1771-8.
53. Hennings H, Glick AB, Lowry DT, Krsmanovic LS, Sly LM, Yuspa SH. FVB/N mice: an inbred strain sensitive to the chemical induction of squamous cell carcinomas in the skin. Carcinogenesis 1993;14: 2353-8.
54. Wu X, Pandolfi PP. Mouse models for multistep tumorigenesis. Trends Cell Biol 2001;11:S2-S9.